One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...

PRGO eyes Q2 results, which are likely to show sales of $1.08 billion, as investors await updates on its Kairos deal and macro pressures.

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...